Compile Data Set for Download or QSAR
maximum 50k data
Found 513 with Last Name = 'riley' and Initial = 'ta'
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM148977(US10512644, Compound Morphine | US8962646, A)
Affinity DataKi:  8.44nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208981((4R,4aR,7S,7aR,12bS)-3-methyl-2,3,4,4a,7,7a-hexahy...)
Affinity DataKi:  8.44nM ΔG°:  -46.1kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  14.3nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  14.3nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425895(US10512644, Compound alpha-6-mPEG1-O-Morphine)
Affinity DataKi:  15.7nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataKi:  15.7nM ΔG°:  -44.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425934(US10512644, Compound 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  17.5nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM209007(US9233167, 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  17.5nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataKi:  22.0nM ΔG°:  -43.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425896(US10512644, Compound alpha-6-mPEG2-O-Morphine)
Affinity DataKi:  22nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425898(US10512644, Compound alpha-6-mPEG4-O-Morphine)
Affinity DataKi:  23.1nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataKi:  23.1nM ΔG°:  -43.6kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  25.9nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425933(US10512644, Compound 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  27.4nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  27.4nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  29.9nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.1nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.1nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.6nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.6nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208986(US9233167, a-6-mPEG5-O-Morphine)
Affinity DataKi:  39.4nM ΔG°:  -42.3kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425899(US10512644, Compound alpha-6-mPEG5-O-Morphine)
Affinity DataKi:  39.4nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  44.3nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425936(US10512644, Compound 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  44.3nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208984(US9233167, a-6-mPEG3-O-Morphine)
Affinity DataKi:  50.7nM ΔG°:  -41.6kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425897(US10512644, Compound alpha-6-mPEG3-O-Morphine)
Affinity DataKi:  50.7nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208988(US9233167, a-6-mPEG7-O-Morphine)
Affinity DataKi:  56.9nM ΔG°:  -41.4kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425901(US10512644, Compound alpha-6-mPEG7-O-Morphine)
Affinity DataKi:  56.9nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208987(US9233167, a-6-mPEG6-O-Morphine)
Affinity DataKi:  73.0nM ΔG°:  -40.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425900(US10512644, Compound alpha-6-mPEG6-O-Morphine)
Affinity DataKi:  73nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425937(US10512644, Compound 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  77.9nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM209010(US9233167, 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  77.9nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425938(US10512644, Compound 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  79.5nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM209009(US9233167, 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  79.5nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425902(US10512644, Compound alpha-6-mPEG9-O-Morphine)
Affinity DataKi:  111nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208989(US9233167, a-6-mPEG9-O-Morphine)
Affinity DataKi:  111nM ΔG°:  -39.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM148977(US10512644, Compound Morphine | US8962646, A)
Affinity DataKi:  118nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208981((4R,4aR,7S,7aR,12bS)-3-methyl-2,3,4,4a,7,7a-hexahy...)
Affinity DataKi:  118nM ΔG°:  -39.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  122nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425939(US10512644, Compound 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  122nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  130nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM425936(US10512644, Compound 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  130nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425903(US10512644, Compound Oxycodone)
Affinity DataKi:  133nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50370595(OXYCODONE | Oxycontin | US1184575, oxycodone | US9...)
Affinity DataKi:  133nM ΔG°:  -39.2kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  148nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  148nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM209007(US9233167, 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  149nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM425934(US10512644, Compound 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  149nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  158nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDelta-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM425939(US10512644, Compound 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  158nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 513 total ) | Next | Last >>
Jump to: